Politics ❯ Legislation ❯ Health Regulations ❯ FDA

Mifepristone

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

The FDA describes an evidence‑driven study now in a data‑gathering phase with no projected timeline.

FDA Approves Second Generic Mifepristone as White House Cites Legal Obligation